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Abstract: A lack of specificity is restricting the further application of conotoxin from Conus bullatus
(BuIA). In this study, an analogue library of BuIA was established and virtual screening was
used, which identified high α7 nicotinic acetylcholine receptor (nAChR)-selectivity analogues.
The analogues were synthesized and tested for their affinity to functional human α7 nAChR and for
the regulation of intracellular calcium ion capacity in neurons. Immunofluorescence, flow cytometry,
and patch clamp results showed that the analogues maintained their capacity for calcium regulation.
The results of the hot-plate model and paclitaxel-induced peripheral neuropathy model indicated
that, when compared with natural BuIA, the analgesia activities of the analogues in different models
were maintained. To analyze the adverse effects and toxicity of BuIA and its analogues, the tail
suspension test, forced swimming test, and open field test were used. The results showed that the
safety and toxicity of the analogues were significantly better than BuIA. The analogues of BuIA with
an appropriate and rational mutation showed high selectivity and maintained the regulation of Ca2+
capacity in neurons and activities of analgesia, whereas the analogues demonstrated that the adverse
effects of natural α-conotoxins could be reduced.
Keywords: conotoxin; nAChR; analgesia; side effects
1. Introduction
Cancer pain, chemotherapy-induced pain, and acute or chronic pain have become a Gordian
knot in clinical practice. Prescription opioids are still the first-line treatments for analgesia, but
their abuse has escalated rapidly, leading to a dramatic increase in cases of opioid dependence and
overdose deaths [1]. As stated in a National Institute of Health (NIH) report, prescription opioids
are the main category of medications presenting abuse liability; the number of prescriptions for
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oxycodone, hydrocodone, and other opioids have escalated from 76 million in 1991 to 207 million in
2013. The increased availability of prescribed opioids has been accompanied by dreadful consequences
related to their abuse. Thus, an alternative therapeutic approach with non-opioid compounds is
essential. Haylie reported a novel therapy based on a non-opioid mechanism that could effectively
treat pain, with a disease-modifying action [2]. Conotoxins are the products of the Conus genus and
are typically a range of cysteine-rich bioactive peptides [3]. Conotoxins, which target dozens of ion
channels and receptors with high selectivity and affinity, can be treated as leading pharmacological
compounds [4,5]. Currently, conotoxins are used for treating cardiogenic diseases and analgesia [6,7].
Ziconotide, ω-conotoxin Conus magus (MVIIA), is an approved drug that targets the calcium channel.
Its mode of action proves that the calcium channel is a potential target for analgesia [8]. Although
ziconotide is an approved analgesic drug, intrathecal injection should be used in clinical practice due
to the blood-brain barrier.
The blood-brain barrier presents a challenge in the development of analgesic peptides. Nicotinic
acetylcholine receptors (nAChRs), members of the ion channel family, play a vital role in modulating
neuronal signaling transmission through the synaptic system at central and peripheral neurons [9].
Due to the high specificity and affinity for different nAChR subtypes, α-conotoxins have been deemed
to be the most precise tools for nAChRs studies, and have shown effects in preclinical testing [10–12].
α9α10 nAChR had been identified and considered as a potential molecular target that can be used for
analgesia. Pioneering work demonstrated that conotoxin Vc 1.1 has a strong analgesic activity, and it
has entered clinical trials for the treatment of chronic pain [13,14]; however, human clinical trials were
terminated due to the negative results of the phase II trials [15].
α7 nAChR can effectively regulate the permeability of calcium ions and modulate physiological
or pathological mechanisms. It has a close relationship with calcium ions and is distributed in
the presynaptic membrane and postsynaptic membrane [16]. When α7 nAChR in the presynaptic
membrane is sensitized, it can accelerate calcium influx and enhance the fusion of the presynaptic
membrane or vesicle [17]. Thus, the presynaptic membrane is depolarized, then the neural transmitters
are released. In the postsynaptic membrane, α7 nAChR plays a vital role in the process of excitatory
signal transduction and adjusting the delivery of gamma-aminobutyric acid (GABA). Gong et al. found
that α7 nAChR was closely related to neuralgia [18]. α7 nAChR has a high conservation rate between
species and is considered a potential candidate target for analgesia. The affinity of BuIA with α7
nAChR plays an important role in analgesia, but the capability of combining it with other types of
nAChRs is the key to side effects and toxicity. Due to the lack of selectivity of BuIA, further applications
of BuIA have been limited. Thus, in this work, BuIA was selected and some analogues were designed
to enhance the selectivity of α7 nAChR. Then, the analogues were synthesized to evaluate the analgesic
activity and the side effects.
2. Results
2.1. Virtual Screening and HPLC Chromatography of Analogues
Molecular Operating Environment (MOE) software (Chemical Computing Group, Quebec,
Canada) (molecular modeling and simulations) was used to analyze the relationship between Conus
bullatus (BuIA) and soluble acetylcholine receptor (PDB ID: 4EZ1). BuIA contains two disulfide bonds
CysI–CysIII and CysII–CysIV and maintains a stable α-helix structure, which plays an important role
in the interaction between BuIA and nAChR. Exploring the structural characteristics and disulfide
connectivity of this complex would provide more information about α-conotoxin–BuIA interactions.
Therefore, we designed a BuIA analogue database and performed virtual screening, where the
interaction sites between two subunits and analogues were selected according to previous work [19–22]
and described in the Methods section. The results showed that the affinity between α7 nAChR subunits
with cotx 2.1 and cotx 2.13 was higher than BuIA, and the affinity between α3, α6, β2, or β4 nAChRs
with cotx 2.1 and cotx 2.13 weakened. However, the affinities between all the nAChRs with Loop1
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analogues weakened (Table 1). Therefore, in this work, cotx 1.1 (GCSSTPPC, Cys I-Cys II) was selected
as the Loop1 analogue. Then, cotx 2.1, cotx 2.13, and cotx 1.1 were designed and synthesized. High
performance liquid chromatography (HPLC) profiles showed that the purities of the cotx 2.1, cotx
2.13, and cotx 1.1 that we synthesized were higher than 95%, and that the compounds therefore
suitable for use in subsequent experiments (Figure 1). The mass spectrometry (MS) results showed
that the molecular weights (MWs) of cotx 2.1, cotx 2.13, and cotx 1.1 were 1281.46, 1293.52, and 747.85,
respectively (Figure S1). In proton nuclear magnetic resonance (1H NMR) and carbon-13 (13C) NMR
spectra, all of the purified analogues had well dispersed signals, which means that in the solution, the
analogues adopted ordered structures (Figures S2–S4).
Table 1. The scores of Conus bullatus (BuIA) and analogues.
Number Sequence α3 α6 β2 β4 α7
BuIA GCCSTPPCAVLYC(CysI–CysIII, CysII–CysVI) −6.657 −5.032 −6.866 −5.485 −7.136
Loop2
cotx 2.1 GSCSTPPSAVLYC (CysI–CysII) −6.531 −4.783 −6.395 −4.544 −7.946
cotx 2.2 GDCSTPPDAVLYC (CysI–CysII) −6.770 −5.060 −6.884 −5.377 −7.636
cotx 2.3 GQCSTPPQAVLYC (CysI–CysII) −6.265 −4.799 −7.536 −4.297 −8.239
cotx 2.4 GMCSTPPMAVLYC (CysI—CysII) −6.878 −4.652 −7.407 −4.472 −8.766
cotx 2.5 GWCSTPPWAVLYC (CysI–CysII) −7.265 −7.348 −7.333 −6.083 −8.073
cotx 2.6 GYCSTPPYAVLYC (CysI–CysII) −7.106 −5.128 −7.123 −6.265 −7.541
cotx 2.7 GTCSTPPTAVLYC (CysI–CysII) −6.259 −4.150 −7.186 −4.711 −7.857
cotx 2.8 GECSTPPEAVLYC (CysI–CysII) −6.605 −3.883 −6.611 −4.528 −7.084
cotx 2.9 GHCSTPPHAVLYC (CysI–CysII) −6.995 −7.399 −8.029 −5.695 −8.570
cotx 2.10 GKCSTPPKAVLYC (CysI–CysII) −7.151 −5.698 −7.412 −4.759 −8.167
cotx 2.11 GRCSTPPRAVLYC (CysI–CysII) −7.315 −5.643 −7.302 −5.565 −8.906
cotx 2.12 KCSTPPSAVLYC (CysI–CysII) −7.267 −5.625 −6.204 −5.173 −7.719
cotx 2.13 KCSTPPDAVLYC (CysI–CysII) −6.358 −4.509 −6.406 −5.363 −7.190
cotx 2.14 KCSTPPQAVLYC (CysI–CysII) −6.448 −6.270 −6.617 −4.347 −7.755
cotx 2.15 HCSTPPSAVLYC (CysI–CysII) −6.203 −5.498 −6.424 −4.907 −7.241
cotx 2.16 HCSTPPDAVLYC (CysI–CysII) −6.451 −5.757 −6.406 −5.069 −7.774
cotx 2.17 HCSTPPQAVLYC (CysI–CysII) −7.002 −6.143 −6.850 −4.313 −7.781
cotx 2.18 RCSTPPSAVLYC (CysI–CysII) −7.177 −4.840 −6.789 −4.531 −8.072
cotx 2.19 RCSTPPDAVLYC (CysI–CysII) −6.930 Neg Neg −5.294 Neg
cotx 2.20 RCSTPPQAVLYC (CysI–CysII) −7.354 Neg Neg −5.259 Neg
Loop1
cotx 1.1 GCSSTPPC (CysI–CysII) −5.834 −4.028 −5.969 −3.186 −6.462
cotx 1.2 GCDSTPPC (CysI–CysII) −5.983 −4.161 −5.718 −3.390 −6.376
cotx 1.3 GCQSTPPC (CysI–CysII) −5.755 −6.275 −5.633 −3.289 −6.651
cotx 1.4 GCWSTPPC (CysI–CysII) −6.281 −6.187 −5.403 −4.900 −6.966
cotx 1.5 GCYSTPPC (CysI–CysII) −6.133 −4.823 −5.710 −5.271 −6.670
cotx 1.6 GCMSTPPC (CysI–CysII) −6.233 −6.329 −5.454 −3.633 −6.392
cotx 1.7 GCTSTPPC (CysI–CysII) −6.353 −4.967 −5.938 −3.553 −6.211
cotx 1.8 GCESTPPC (CysI–CysII) −6.151 −3.414 −5.640 −3.669 −6.249
cotx 1.9 GCHSTPPC (CysI-CysII) −6.045 −6.565 −5.506 −3.648 −6.010
cotx 1.10 GCKSTPPC (CysI–CysII) −5.956 −4.409 −5.532 −3.282 −6.450
cotx 1.11 GCRSTPPC (CysI–CysII) −6.373 −6.403 −5.770 −4.116 −6.370
Molecules 2019, 24, 337 4 of 15
Molecules 2019, 24 FOR PEER REVIEW  4 
 
 
Figure 1. The design and the HPLC chromatography of (A) cotx 2.1, showing a purity of 98.826%; (B) 
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Then, the calcium levels in the dorsal root ganglion (DRG) neuron cells were investigated by 
immunofluorescence and flow cytometry. The results showed that after being treated with BuIA and 
its analogues, the calcium levels in Dorsal Root Ganglion (DRG) neuron cells decreased (Figure 2A,B). 
As per a previous study [23], the patch clamp was used to detect the influence of BuIA and its 
analogues on Ca2+ in DRG cells. The results showed that BuIA and its analogues could induce calcium 
channel closure. The inhibitions of cotx 2.1 and cotx 2.13 were stronger than BuIA and cotx 1.1, 
although the inhibitions of BuIA and cotx 1.1 did not show obvious differences (Figure 2C). 
Figure 1. The design and the HPLC chromatography of (A) cotx 2.1, showing a purity of 98.826%; (B) of
cotx 2.13, showing a purity of 99.215%; and (C) cotx 1.1, showing a purity of 95.573%.
2.2. Affinity and Activity of BuIA and Analogues
In this work, we analyzed the affinities of BuIA and its analogues with human α7 nAChR.
Compared with the BuIA, the affinity between human α7 nAChR and cotx 2.1 or cotx 2.13 was
significantly enhanced (p < 0.05). Although the affinity between the human α7 nAChR and cotx
1.1 was ea er, the ffinity of BuIA and cotx 1.1 was in the same order of magnitude (Table 2 nd
Table S5). Then, the calcium levels in the dorsal root ganglion (DRG) neuron cells were investigated by
immunofluorescence and flow cytometry. The results showed that after being treated with BuIA and
its analogues, the calcium levels in Dorsal Root Ganglion (DRG) neuron cells decreased (Figure 2A,B).
As per a previous study [23], the patch clamp was used to detect the influence of BuIA and its analogues
on Ca2+ in DRG c lls. The results sh wed that BuIA and its analogues could indu calcium cha nel
cl sure. The i hibitions of cotx 2.1 and cotx 2.13 w re stronger than BuIA nd cotx 1.1, although the
inhibitions of BuIA and cotx 1.1 did not show obvious differences (Figure 2C).
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Table 2. The affinity of BuIA or its analogues with functional α7 nicotinic acetylcholine receptor (nAChR).
Peptide EC50 (nM)
BuIA 19.7 ± 2.85
cotx 2.1 12.3 ± 1.07
cotx 2.13 15.4 ± 1.6
cotx 1.1 26.6 ± 4.8Molecules 2019, 24 FOR PEER REVIEW  5 
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were incubated with BuIA and its analogues: BuIA and all of the analogues significantly reduced the 
calcium concentration in DRG cells; (C) the results of the calcium channel state in the DRG neuron 
cells. The patch clamp was used and the cells were treated with BuIA and its analogues: BuIA and all 
of the analogues inhibited the calcium channel on the DRG cell surface. The inhibitions of cotx 2.1 and 
cotx 2.13 were significantly higher than BuIA and cotx 1.1, and the differences between BuIA groups 
and cotx 1.1 groups had no statistical significance. 
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cotx 2.1 12.3 ± 1.07 
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2.3. Analgesic Activity of BuIA and Analogues In Vivo 
The analgesic activities of BuIA and its analogues were evaluated using the hot-plate test model 
and the paclitaxel-induced peripheral neuropathy model. In the hot-plate test model, when compared 
to the control group after injection, the licking time of BuIA and the analogue groups significantly 
expanded (p < 0.05), but the difference between the BuIA group and analogue groups was not 
statistically significant (p > 0.05). Further analysis showed that the efficacy times of cotx 2.1 and cotx 
2.13 were quicker than BuIA and cotx 1.1 (Figures 3A and S6). When the paclitaxel-induced peripheral 
Figure 2. Activity of BuIA and its analogues on Ca2+ levels in the dorsal root ganglion (DRG) neuron
cells: (A) immunofluorescence images of calcium in the DRG neuron cells that were treated with BuIA
and its analogues: BuIA and all of the analogues significantly weakened the fluorescence intensity of
intracellular calcium ion staining; (B) flow cytometry results of calcium in the DRG neuron cells that
were incubated with BuIA and its analogues: BuIA and all of the analogues significantly reduced the
calcium concentration in DRG cells; (C) the results of the calcium channel state in the DRG neuron cells.
The patch clamp was used and the cells were treated with BuIA and its analogues: BuIA and all of the
analogues inhibited the calcium channel on the DRG cell surface. The inhibitions of cotx 2.1 and cotx
2.13 were significantly higher than BuIA and cotx 1.1, and the differences between BuIA groups and
cotx 1.1 gr ups had no statistical significance.
2.3. Analgesic Activity of BuIA and Analogues In Vivo
The analgesic activities of BuIA and its analogues were evaluated using the hot-plate test model
and the paclitaxel-induced peripheral neuropathy model. In the hot-plate test model, when compared
to the control group after injection, the licking time of BuIA and the analogue groups significantly
expanded (p < 0.05), but the difference between the BuIA group and analogue groups was not
statistically significant (p > 0.05). Further analysis showed that the efficacy times of cotx 2.1 and
cotx 2.13 were quicker than BuIA and cotx 1.1 (Figure 3A and Figure S6). When the paclitaxel-induced
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peripheral neuropathy model was applied, the hyperalgesias of BuIA and analogue groups improved
significantly (p < 0.05). There were no significant differences within the BuIA group and the analogue
groups (p > 0.05) (Figure 3B).
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test, tails suspension test, and forced swimming test were used to analyze the changes in autonomic 
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Figure 3. Analgesic activity of BuIA and analogues. Bar graphs represent the mean ± SEM, * p < 0.05:
(A) Hot-plate test model: control group treated with saline. The BuIA group was treated with 1.5 mg/kg
BuIA, the cotx 2.1 group was treated with 1 mg/kg cotx 2.1, the cotx 2.13 group was treated with
1.5 mg/kg cotx 2.13, and the cotx 1.1 group was treated with 2 mg/kg cotx 1.1. Variance analysis showed
that the licking times of the BuIA and analogue groups were significantly higher than the control group
(F = 5.608, p < 0.05). (B) Paclitaxel-induced peripheral neuropathy model: the control group was treated
with saline. The paclitaxel model, with the BuIA and analogue groups intraperitoneally injected with
paclitaxel (10 mg/kg), was used to establish the models. After 24 h, the paclitaxel model group was
treated with saline, the BuIA group was treated with 1.5 mg/kg BuIA, the cotx 2.1 group was treated
with 1 mg/kg cotx 2.1, the cotx 2.13 group w s treated with 1.5 mg/kg cotx 2.13, and the cotx 1.1 group
was reated with 2 mg/kg cotx 1.1. Variance analysis howed tha the hyperalgesia of BuIA and
analogue groups were significantly igher than the control group. How ver, the differences between
the BuIA and analogue groups were not statistically significant (F = 3.849, p < 0.05).
2.4. Adverse Reactions to BuIA and Analogues
Th re is a clos relationship b tween α7 nAChR and autonomic movement, so the open field
test, tails suspension test, and forced swimming test were used to analyze the changes in autonomic
movement after the mice were treated with BuIA and the analogues. All the results showed that cotx 2.1,
cotx 2.13, and c tx 1.1 did not affect the autonomic movement of mice (Figure 4). However, when
compared with the control group, BuIA weakened the autonomous movement of mice significantly
(p < 0.05). Twenty-four hours later, there were no significant differences between all of the groups
(p > 0.05) (Figure 4).
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Figure 4. Adverse reactions of BuIA and analogues. Bar graphs represent the mean value ± SEM,
* p < 0.05. (A) Open field test—total distances: the total distances of the analogue groups and control
group had no significant differences (p > 0.05), but the BuIA group was significantly lower than the other
groups (p < 0.05); (B) open fi ld test—frequency entering peripheral are : the frequency entering the
p ipheral area of the anal gue groups and control group showed no significant diffe nces (p > 0.05),
but the BuIA group was sig ificantly lower than the other gro s (p < 0.05); (C) open fiel test—center
distance: the center distance of the analogue groups and control group had no significant differences
(p > 0.05), but the BuIA group was significantly lower than the other groups (p < 0.05); (D) open
field test—peripheral distance: the peripheral distance of the analogue groups and control group
had no significant differences (p > 0.05), but the BuIA group was significantly lower than the other
groups (p < 0.05); (E) open field test—residence time in central area: the residence time in the central
area of the analogue groups and control group had no significant differences (p > 0.05), but the BuIA
group was significantly lower than the other groups (p < 0.05); (F) open field test—residence time in
peripheral area: the residence time in the peripheral area of the analogue groups and control group
had no significant differences (p > 0.05), but the BuIA group was significantly higher than the other
groups (p < 0.05); (G) the tails suspension test—tail suspended motion times: the tail suspended motion
times of the analogue groups and control group demonstrated no significant differences (p > 0.05),
but the BuIA group was significantly lower than the other groups (p < 0.05); (H) forced swimming
test—forced swimming times: the forced swimming times of the analogue groups and control group
had no significant differences (p > 0.05), but the BuIA group was significantly lower than the other
groups (p < 0.05).
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3. Discussion
Ion channels are important analgesic targets. Ziconotide, with low addiction potential and
good effect, has been approved for clinical use, although intrathecal administration has limited its
clinical application due to the blood–brain barrier. Therefore, peripheral ion channels are receiving
increased attention. As reviewed by Vink and Alewood [24], α7 and α9α10 are the peripheral targets
for inflammatory and neuropathic pain. Azam [25] described the activity of α-conotoxin BuIA on 10
different nAChRs with genetic mutations and the results showed that BuIA can block different types of
nAChRs. Normally, compounds with low specificity likely produce more side effects. Therefore, we
established an analogue library based on BuIA to find an analogue that specifically targets α7 nAChR.
In this work, α7 nAChR was selected as the peripheral analgesia target, so α-conotoxin BuIA, which
can target α7 nAChR and other types of nAChRs, was selected to design analogues with high α7
nAChR specificity.
Yu et al. [23] found that the deletion of a disulfide bridge in α-conotoxins did not strongly influence
its overall structure and activity, but they added another linker to maintain the binary ring structure.
The question of whether the deletion of the disulfide bridge had an effect on specificity needed to
be confirmed. Therefore, we designed a single disulfide bridge mutant library without adding any
linker and analyzed whether analogues with higher specificity could be obtained. As Cuny [19] stated,
Loop2 is an important factor in determining the selectivity of α-conotoxin. Therefore, in this work,
we analyzed the complex structure of BuIA and acetylcholine binding protein and treated BuIA-Cys8
as the component of Loop2. Neutral or hydrophilic amino acids were used to replace BuIA-Cys8,
according to the characteristics of Cys. Although the conotoxin selectivity was attributable to Loop
2, the sequences of Loop 1 and Loop 2 have high repeatability. Servents’ [26] research showed that
the key residue for the inhibition of nAChRs by α-conotoxin ImI was the Asp-Arg-Pro motif in the
overlapping areas of Loop1 and Loop2. Therefore, in this work, we wanted to confirm whether Loop1
could enhance selectivity, so alterations to Loop 1 were performed. The results showed that that the
analogues of Loop1 could not significantly improve the selectivity of α7 nAChR, but that the affinity
to other receptor subtypes was diluted. Therefore, we speculated that this was the reason why cotx
1.1 would have similar activity to Loop2 analogues at high dosages. Next, we wanted to obtain the
analogues that had a strong affinity with α7 nAChR and maintain the affinity between the other
subtypes of nAChRs. The virtual screening results showed that cotx 2.1 and cotx 2.13 could match
the requirements, but all of the Loop1 analogues did not enhance their affinity with any subtype of
nAChR. Therefore, the analogue with a high affinity for α7 nAChR and the same mutation pattern as
cotx 2.1 was selected for further research.
Subsequently, cotx 2.1, cotx 2.13, and cotx 1.1 were synthetized with solid phase peptide synthesis
(SPPS) and the purity met all requirements. The 1H NMR spectra showed that all of the purified
analogues had well dispersed signals, which meant that the analogues had adopted ordered structures
in the solution. We investigated the affinity between BuIA and its analogues and human α7 nAChR by
microscale thermophoresis analysis [27,28]; the affinity between the functional α7 nAChR protein and
cotx 2.1 and cotx 2.13 was enhanced. However, the affinity between the α7 nAChR protein and cotx 1.1
decreased. Due to the changes in structure and sequence, the orientation of cysteine changed, causing
the core sequences to be more exposed to the combination of BuIA analogues, and α7 nAChR was
strengthened. cotx 1.1, lacking one loop structure, showed that the connection with α7 nAChR weakened.
A Fluo-4 AM (AAT Bioquest Inc, Sunnyvale, CA, USA) probe was utilized to mark the calcium
ion in rat DRG = neurons cells. Flow cytometry and fluorescence microscope analysis showed that
BuIA and its analogues could significantly reduce the calcium ion levels in the DRG cells, but the
inhibition of BuIA and its analogues showed no significant differences (p > 0.05). The patch clamp
results showed that BuIA and all of its analogues could limit the circulation of the calcium flux. Based
on these results, the hot-plate test model and paclitaxel-induced peripheral neuropathy model were
used to assess the analgesic activity of BuIA and its analogues.
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Side effects and the safety of the analgesic compounds are vital to drug development [29], so we
also tested the side effects and the toxicity of BuIA and its analogues. The toxicity of all compounds
were tested using Caenorhabditis elegans (C. elegans). And the analogues could maintain the heat
resistance threshold and hyperalgesia of BuIA, whereas the side effects and the toxicity (Supplementary
Material Figure S7) of the analogues were weaker compared with BuIA. Low specificity is the key to
causing sides effects. So, effectively enhancing the selectivity is one of the important ways to reduce
side effects. And this is the reason that the cotx 2.1 and cotx 2.13 could maintain the analgesia activity
and weaken the side effects.
In this work, we synthesized single disulfide analogues, cotx 2.1, cotx 2.13, and cotx 1.1, without
changing the pairing models of disulfide (CysI-CysIII and CysII-CysIV). Compared with the natural
BuIA, the structures of these analogues were simplified, which improved the efficiency of their synthesis
with better quality, as well as being faster and cheaper. As in previous studies, single disulfide conotoxin
analogues could be developed into new analgesic leading compounds [30]. In our work, the results
showed that the cotx 2.1 and cotx 2.13 mutations of BuIA could enhance selectivity with α7 nAChR
and adjust the calcium flow into the DRG neuron cells. All of the analogues maintained the analgesic
activity of BuIA, and the analogues also had low toxicity and reduced adverse reactions in vivo. This
suggests that the deletion of the disulfide bridge of α-conotoxin not only maintained activity, but also
enhanced the selectivity and obtained highly specific targeted analogues by the appropriate mutation
methods. However, α7 nAChR is closely related to the treatment of inflammatory pain, which is highly
correlated with astrocytes. Therefore, whether the analogues combined with drugs that regulate the
astrocyte can enhance analgesic activity remains to be studied. Intracranial α7 nAChR is closely related
to depression and Parkinson’s disease. Next, we will modify the structure of cotx 2.1 or cotx 2.13 via
side chain modifications, and use the strapped peptide strategy to cross the blood–brain barrier and
analyze the potential for the treatment of other diseases such as Parkinson’s disease.
4. Materials and Methods
4.1. Analogue Design and Siftings
Based on the crystal structure of acetylcholine binding protein (AChBP) in complex with
α-conotoxin BuIA (PDB ID:4EZ1), BuIA-Cys8 plays a vital role in binding to the AChBP, which is also
a key in maintaining the structure of BuIA. Loop2 is an important factor determining the selectivity of
α-conotoxin [19]. Therefore, in this work, we treated BuIA-Cys8 as the component of Loop2. According
to the characteristics of Cys, neutral amino acids or hydrophilic amino acids were used to replace
BuIA-Cys8 and BuIA-Cys2. Lys, Arg, and His (basic and hydrophilic amino acids) were used instead of
BuIA-Cys2, and BuIA-Gly1 was deleted, while BuIA-Cys8 was replaced with Asp, Gln, and Ser (neutral
and hydrophilic amino acids). The analogues of Loop1 were established, BuIA-Cys3 was replaced with
neutral amino acids or hydrophilic amino acids, and the amino acids from BuIA-Ala9 to BuIA-Cys13
were deleted. As Azam [25] demonstrated, BuIA can combine with α3, β2, β4, α6, and α7 nAChR
subunits, so the α3 (PDB ID:5T90), β2 (PDB ID: 5KXI), β4 (PDB ID:5T90), α6 (PDB ID:2BYP), and α7
(PDB ID:3SQ6) structures were download from PDB. According to previous research, the docking sites
(α3 [20], β2 [19], β4 [19], α6 [21] and α7 [22]) which were between two subunits were selected; then,
the Molecular Operating Environment (MOE) 2009 software (2009, Montreal, Canada) was used for
docking, and the scoring functions were Triangle Matcher and Forcefield.
4.2. Peptide Preparation
BuIA was purchased from GenScript (GenScript, Nanjing, China), whereas GL Biochem (GL Biochem,
Shanghai, Chinae supplied H-Cys(Trt)-2-CTC resin and amino acids. The fluorenylmethyloxycarbonyl
(Fmoc) solid phase peptide synthesis (SPPS) methods were used to synthesize all the analogues
using the Focus XC system (AAPPTec, Louisville, KY, USA). N,N′-diisopropylcardodiimide (DIC)
and 1-hydroxbenzotriazole (HOBt) were applied as a peptide coupling reagent and piperidine
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(PIP) was chosen as a deprotection reagent in the synthesis process. In the process of cleavage, 90%
trifluoroacetic acid (TFA) solution was selected as a cleavage buffer, and ether was used as a settling
agent. Peptides were dissolved in acetonitrile and aqueous buffer (pH 8.0, 1 mg/mL) overnight for
oxidative cyclization. An AlltimaTM C18 column (4.6 × 250 nm) (Agilent Technologies Inc, Santa Clara,
CA, USA) was used to purify the crude peptide with eluent monitor at 220 nm. When the HPLC was
operated, 0.065% trifluoroacetic acid in 100% water was prepared as buffer A, and buffer B was 0.05%
trifluoroacetic acid in 100% acetonitrile. The flow speed was set to 1 mL/min. The same conditions
were used in HPLC-MS (LCMS 2000, SHIMADZU, Kyoto, Japan) analysis to confirm the purity and
molecular mass of the analogues. All analogues were dissolved in D2O (J&K Scientific, Beijing, China),
then a Bruker AVANCE AV-500 (Bruker Daltonics Inc., San Diego, CA, USA) was used to record the
spectra. The NMR experiments included 13C-NMR and 1H-NMR.
4.3. Microscale Thermophoresis Analysis
Besides the radioligand assay [31,32] and surface plasmon resonance (SPR) [33], microscale-
thermophoresis (MST) is another technique used to analyze the interaction between the receptor
and ligand based on the thermal motion of biomolecules [34]. Human functional receptor protein
(α7 nAChR) was purchased from Cloud-Clone Corp (Cloud-Clone Corp, Houston, TX, USA); this
was first dissolved into a buffer solution that did not contain primary amine compounds. The buffer
solution was exchanged through a mixed column A. Then, Cy5 fluorescent dye (Ruixin Biological
Technology, Xi’an, China) was added to stain the recombinant protein and purify the labeled protein
through the purified column B. Finally, the analogues were diluted by a certain proportion and mixed
with the labeled protein one to one, incubated at room temperature for 5 min, and the relevant
instrument parameters were set. Monolith NT.115 (NanoTemper, Munich, Germany) and NT-Analysis
software (NanoTemper, Munich CITY, Germany) were used to record and analyze the data.
4.4. Dorsal Root Ganglion Neuron Cell Preparation
The 120–160 g Wistar rats were killed by cervical dislocation and the ganglia was enzymatically
dissociated to obtain the dorsal root ganglion (DRG) neuron cells. The operation procedures were
investigated and approved by the Animal Ethics Committee of China Pharmaceutical University
(SYXK(SU)2016-0011). Normal feeding occurred for at least three days for the animals to adapt to
the environment, and we ensured that the mice had a free water supply during the experiment.
As described in the literature [23,35], the ganglia were rinsed in ice-cold Hank’s Balanced Salt
Solution (HBSS) (Life Technologies, Carlsbad, CA, USA) and incubated in HBSS buffer containing
1.5 mg/mL type 2 collagenase (Sigma-Aldrich Inc., Milwaukee, WA, USA) at 37 ◦C for 30 min. Then,
Dulbecco’s Modified Eagle’s Medium (DMED) (Gibco, Carlsbad, CA, USA), supplemented with 1%
penicillin/streptomycin and 10% fetal calf fetal (Biological Industries, Kibbutz Beit Haemek, Israel)
was used to rinse the ganglia three times and triturated with Pasteur pipettes. The DRG neuron cells
were plated on a poly-D-lysine (Beyotime, Shanghai, China)/laminin (Sigma-Aldrich, Milwaukee,
USA)-coated plate (Thermo Fisher, Massachusetts, MA, USA), incubated at 37 ◦C in 5% CO2 at a
relative humidity of 95%. All cells were used within 48 h.
4.5. Fluorescence Imaging Analysis
The fluorescence labeling technique was used to combine the studied protein with some
fluorescent substances, and uses its fluorescence properties to provide a range of information about
the protein [36]. Fluo-4 acetyloxymethyl (AM) is an acetyl methyl ester derivative of Fluo-4 that can be
cleaved by intracellular esterase to Fluo-4. Fluo-4 binds to calcium ions to produce strong fluorescence
with a maximum excitation wavelength of 494 nm and a maximum emission wavelength of 516 nm [37].
A certain number of analogues and natural α-conotoxins were accurately measured. Sample solutions
with a concentration of 100 nM were prepared using serum-free DMEM medium with the DRG neuron
cells as a culture object. After 4 h, the cells were rinsed with phosphate buffer saline (PBS) several
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times, then 2 µM of Fluo-4 AM calcium ion fluorescent dye (AAT Bioquest Inc, Sunnyvale, CA, USA)
was added to each hole, and the cells were incubated for 30 min at room temperature. Results were
observed and recorded under a fluorescence microscope (OLYMPUS IX53, Tokyo, Japan), where the
fluorescence imaging analysis was repeated three times.
4.6. Flow Cytometer Analysis
Flow detection technology is a multi-parameter, rapid quantitative analysis and sorting technique
for cells and biological particles in rapid linear flow. An analogue and BuIA were accurately measured.
Sample solutions with a concentration of 100 nM were prepared using serum-free DMEM medium and
using the DRG neuron cells as a culture object. After 4 h, the cells were rinsed with PBS several times,
and 500 µL of Fluo-4 AM calcium ion fluorescent dye and 1 µg/mL of calcium ionomycin were added to
each hole. Then, the cells were incubated at room temperature for 30 min. Two independent validations
were performed for flow cytometer analysis, then the samples were detected by a MACSQuant flow
cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany) and FlowJo 7.6 (FlowJo LLC, Ashland, AL,
USA) was used to analyze the data.
4.7. Patch Clamp Electrophysiology
The patch clamp is a membrane that is touched by a micro-glass electrode, which is connected
by resistance above a gigabit; then, the ion current (pA level) of the ion channel on the membrane is
detected and recorded [38]. The analogues and BuIA were measured. Sample solutions were prepared
by using serum-free DMEM medium and DRG nerve cells as the culture object. The whole-cell
configuration of the patch clamp technique with a QPatch-16 workstation (Sophion, Ballerup, Denmark)
was used to record the membrane currents in the DRG neurons. The external recording solution
contained the following: 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer,
10 mM D-glucose, 150 mM tetraethylammonium-Cl, and 2 mM BaCl2 at pH 7.3. The internal solution,
which contained 10 mM HEPES, 1 mM MgCl2, 140 mM CsCl, 0.1 mM Na-GTP, 4 mM MgATP, and
5 mM 1,2-bis(O-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid tetracesium salt-Cs4 at pH 7.3,
was used to the fill the fire-polished record electrodes. During recording, a gravity-fed perfusion
system was used to perfuse the DRG neurons with external recording at a flow rate of 1 mL/min.
The currents of the DRG neuron cells of each group were detected with the QPatch-16 workstation
(Sophion, Ballerup, Denmark) and data were processed with supporting software. In order to verify
the reliability of the results, we also carried out two repeated experiments.
4.8. Animals
Female Kunming mice (20–25 g) and Wistar rats (120–160 g) used in this study were obtained
from the Experimental Animal Center of Qinglong Mountain in Nanjing, China. The animals were
maintained until 7–8 weeks old. Normal feeding occurred for at least three days for the animals to
adapt to the environment, and we ensured that the mice had a free water supply during the experiment.
All the mice were cared for according to the Provisions and General Recommendation of Chinese
Experimental Animals Administration Legislation (SYXK(SU)2016-0011).
4.8.1. Hot-Plate model Test
The mice were placed on an enclosed hot plate (Yuyan instruments, Shanghai, China). The plate
temperature was set at 55± 0.5 ◦C. The time (hot plate pain threshold) was recorded and the mice were
removed from the enclosed hot-plate when the mice licked a hind paw. The mice were first screened
for pain threshold and were retained between 10–30 s. The screened mice were divided into the blank
group, BuIA group, and the analogues groups with 12 mice in each group. The control group was
treated with saline, the BuIA group was treated with 1.5 mg/kg BuIA, the cotx 2.1 group was treated
with 1 mg/kg cotx 2.1, the cotx 2.13 group was treated with 1.5 mg/kg cotx 2.13, and the cotx 1.1 group
was treated with 2 mg/kg cotx 1.1. According to the group, mice in each group were intraperitoneally
Molecules 2019, 24, 337 12 of 15
injected with physiological saline, BuIA, or the analogues. After 0, 30, 60, and 90 min, the hot plate was
used and the hot plate pain threshold was recorded for each group of mice.
4.8.2. Paclitaxel-Induced Peripheral Neuropathy Model
The mice were divided into a blank group, model group, BuIA group, and analogues groups with
12 mice in each group. Then, the mice in the model group, BuIA group, and analogues groups were
treated with 10 mg/kg paclitaxel (Biopurify, Chengdu, China) with intraperitoneal injection. After
24 h, according to the group, the mice in each group were intraperitoneally injected with physiological
saline. The control group was treated with saline, the BuIA group was treated with 1.5 mg/kg BuIA,
the cotx 2.1 group was treated with 1 mg/kg cotx 2.1, the cotx 2.13 group was treated with 1.5 mg/kg
cotx 2.13, and the cotx 1.1 group was treated with 2 mg/kg cotx 1.1. After 0 h, 1 h, and 2 h, the Von Frey
Hairs were used to test the hyperalgesia. Yuyan Instruments (Yuyan Instruments, Shanghai, China)
supplied the hot plate analgesia test meter and the Von Frey Hairs instrument was purchased from
North Coast Medical (North Coast Medical Inc., Morgan Hill, CA, USA).
4.9. Detection of Side Reaction Activity
4.9.1. Tail Suspension Test
The mice were randomly divided into a blank group, BuIA groups, and analogues groups with
10 mice in each group. Mice in each group were intraperitoneally injected with physiological saline,
BuIA, or the analogues. The control group was treated with saline; and the BuIA group, cotx 2.1 group,
cotx 2.13 group, and cotx 1.1 group were treated with 5 mg/kg BuIA, cotx 2.1, cotx 2.13, or cotx 1.1,
respectively. The mice were kept motionless for a while after being hung, and the inactivity time
within 5 min was recorded [39,40].
4.9.2. Forced Swimming Test
The mice were randomly divided into a blank group, BuIA groups, and analogues groups with 10
mice in each group. Mice in each group were intraperitoneally injected with physiological saline, BuIA,
or the analogues, respectively. The control group was treated with saline, and the BuIA group, cotx 2.1
group, cotx 2.13 group, and cotx 1.1 group were treated with 5 mg/kg BuIA, cotx 2.1, cotx 2.13 or cotx
1.1, respectively. The mice were kept motionless for a while in the swimming state and the inactivity
time in 5 min was recorded [40].
4.9.3. Open Field Test
The mice were randomly divided into a blank group, BuIA groups, and analogues groups with 10
mice in each group. Mice in each group were intraperitoneally injected with physiological saline, BuIA,
or the analogues, respectively. The control group was treated with saline and the BuIA group, cotx 2.1
group, cotx 2.13 group, and cotx 1.1 group were treated with 5 mg/kg BuIA, cotx 2.1, cotx 2.13 and cotx
1.1, respectively. The behavioral indicators (total distances, frequency entering peripheral area, center
distance, peripheral distance, residence time in central area, residence time in peripheral area) of mice
in the open field box in 5 min were observed and recorded [41].
4.10. Data Analysis
All data processing was conducted using special software, and the details are described in the
materials and methods section, whereas the NMR spectroscopy data were analyzed with MestReNova
(Mestrelab Research SL, Santiago de Compostela, Spain). The measurement data were analyzed by
GraphPad Prism 5 (GraphPad software Inc., San Diego, CA, USA), then a two-way ANOVA was used
to test the data differences between the groups.
Molecules 2019, 24, 337 13 of 15
5. Conclusions
In conclusion, we screened and synthesized novel BuIA analogues that targeted α7 nAChR
specificity based on the BuIA analogue library. Although we simplified the structure of conotoxin BuIA
by mutating the amino acid and deleting a disulfide bond, all of the analogues analgesic activities
could improve the safety and reduce the incidence of adverse reactions to autonomic movement.
However, research on the further possibility of cotx 2.1 or cotx 2.13 for the treatment of diseases such as
Parkinson’s disease needs to be undertaken to improve its potential as an analgesic drug. Finally, the
pharmacokinetics and preparation are obstacles in the next stage.
6. Patents
Xu Hanmei, Qi Weiyan, Liu Chen, and Wu Pengxiang. The peptide with analgesic activity and its
application [P]. Jiangsu: CN107759665A, 2018-03-06.
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analysis of BuIA and analogues.
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